Levomepromazine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2010, Pages

  Sivaraman, Parthipan ^a   Rattehalli, Ranganath D ^b   Jayaram, Mahesh B ^c  

^a SHEFFIELD HEALTH AND SOCIAL CARE NHS FOUNDATION TRUST   (United Kingdom)

^b Assertive Outreach Team   (United Kingdom)

^c LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE;

HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; HUMANS; METHOTRIMEPRAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 84855427396     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007779.pub2     Document Type: Review

References (72)

1. Angst J, Jaenicke U, Padrutt A, Scharfetter C. Ergebnisse eines Doppelblindversuches von HF 1854 (8-Chlor-11-(4 methyl-1-piperazinyl)-5H-dibenzo (b,e) (1,4) diazepin) im Vergleich zu Levomepromazin. Pharmakopsychiatrie und Neuropsychopharmakologie 1971;4:192-200.
2. Baker AA, Thorpe JG. Assessing a new phenothiazine. Journal of Mental Science 1958;104:855-9.
3. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology 1996;16(1):38-44.
4. Blin O, Azorin JM, Bouhours P. Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics 1992;51(2):189.
5. Blin O, Azorin JM, Bouhours P. Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology 1992;106:31-2.
6. Blin O, Azorin JM, Bouhours P. Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry 1991;29:388.
7. Blin O, Azorin JM, Bouhours P, Fondarai J. Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. 9th World Congress of Psychiatry; 1993 Jun 6-12; Rio de Janeiro, Brazil. France, 1993:24.
8. Blin O, Azorin JM, Bouhours Ph, Fondarai J. Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology 1992;15(Suppl 1. Pt B):169B.
9. Tatossian A. Comparitive double-blind trial of the efficacy of risperidone, haloperidol and levomepromazine (methotrimeprazine) in patients with an acute exacerbation of schizophrenia presenting psychotic anxiety symptoms. Clinical report 1991.
10. Lal S, Thavundayil JX, Nair NPV, Annable L, Kin NMKNY, Gabriel A, et al. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Journal of psychiatry & neuroscience: JPN 2006;31(4):271-9.
11. Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8.
12. Andersson SB, Forshell GP, Schulman A, Wetterberg L, Asaba H. Levomepromazine elimination in patients during active and sham hemodialysis. Artificial Organs 1983;7(3):340-3.
13. Blaha L, Zenglein R, Wiedmayer J. Therapy of acute schizophrenic attacks. High dosage haloperidol therapy compared with a two component treatment [Zur therapie akuter schizophrenie-schube. Hochdosierte haloperidol-behandlung im klinischen vergleich mit einer zweizugel-therapie]. Fortschritte der Medizin 1979;97(23):1095-100.
14. Hicklin A, Angst J. Retrospective and prospective studies on the clinical effect of clopenthixol (sordinol) in endogenous phychoses [Retrospektive und prospektive Studie uber die klinische Wirkung von Clopenthixol (Sordinol) bei endogenen Psychosen]. Schweizerische Medizinische Wochenschrift 1967;97(19):615-21.
15. Higashima M, Takeda T, Nagasawa T, Hirao N, Oka T, Nakamura M, et al. Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. European Psychiatry 2004;19(6):380-1.
16. Horacek J, Janu L, Seifertova D. The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia. Schizophrenia Research 2004;67(1):168.
17. Horacek J, Seifertova D, Janu L, Petranova T. The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13, Davos, Switzerland. 2004.
18. Kalinin VV, Rudik VA. The place of insulin coma therapy among modern methods of treatment of paroxysmal schizophrenia patients. Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova 1986;86(5):745-9.
19. Kojima T, Shimazono Y, Ito H, Comparison of clinical effects of etizolam, nitrazepam and levomepromazine on schizophrenic sleep disturbance using double-blind technique. Seishin Igaku (Clinical Psychiatry) 1983;12(10):1293-314.
20. Leitch A, Seager CP. A clinical trial of four tranquillizing drugs. Journal of Mental Science 1960;106:1093-8.
21. Makaric G, Folnegovic-Smalc V, Folnegovic Z, Mimica N. Agitation in acute episode of schizophrenia: carbamazepine treatment in combination with haloperidol versus combined neuroleptics. Schizophrenia Research 2000;41(1):210.
22. Milne HB, Fowler DB. A clinical trial of largactil (chlorpromazine), stemeticl (prochlorperazine) and veractil (methotrimeprazine). Journal of Mental Science 1960;106:1105-10.
23. Moller HJ. Incidence of EPS under risperidone therapy. 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France. 1992:32.
24. Moller HJ. Incidence of EPS under risperidone therapy. 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France. 1992:32.
25. Nahunek K, Rodova A, Svestka J. Outline classification of neuroleptic drugs based on results of short-term control crossed studies in schizophrenia [Pokus o klasifikaci neuroleptik na podklade vysledku kratkodobych kontrolovanych zkrizenych studii u schizofrenie]. Ceskoslovenska Psychiatrie 1976;72(2):104-14.
26. Nakajima M, Terao T, Iwata N, Nakamura J. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: Effects on hyperprolactinemia. Pharmacopsychiatry 2005;38(1):17-9.
27. Pancheri P. Risperidone: efficacy on affective and mood-related symptoms. 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France. 1992:30-1.
28. Pecknold JC, Ananth JV, Ban TA, Lehmann HE. The use of methyldopa in schizophrenia: a review and comparative study. American Journal of Psychiatry 1972;128(10):1207-11.
29. Quinn PJG, Johnston J, Latner G, Kiloh LG. A comparative controlled trial of methotrimeprazine ('veractil') in chronic schizophrenia. Journal of Mental Science 1960;106:160-71.
30. Schnetzler J, Chalon N, Chaleat J, Pochat Y. Experimental studies on the dream reports of psychotic, neurotic and normal subjects: Ego functions and the influence of neuroleptics [Etudes experimentales sur les recits de reves de sujets psychotiques, nevrotiques et normaux. Fonctions du Moi. Influence des neuroleptiques]. Annales Medico-Psychologiques 1973;131(2):187-205.
31. Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. International Journal of Neuropsychopharmacology 2007;10(3):321-33.
32. Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, et al. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Therapeutic Drug Monitoring 1997;19:261-4.
33. Vinar O. Differences in therapeutic effects of phenothiazine drugs. Agressologie 1968;9(2):315-7.
34. Vinar O, Taussigova D. Schizophrenic syndromes improving without neuroleptic drug treatment [Schizofrenni syndromy zlepsujici se bez neurolepticke lecby]. Ceskoslovenska Psychiatrie 1976;72(3):176-81.
35. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006;63(10):1079-87.
36. Adams CE, Jayaram M. Do findings from new trials for schizophrenia fit with existing evidence: not duped..just beguiled?. Epidemiologia e Psichiatria Sociale 2007;16(3):199-02.
37. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
38. Marie Asberg, Borje Cronholm, Folke Sjoqvist, Dick Tuck. Correlation of Subjective Side Effects with PlasmaConcentrations of Nortriptyline. BMJ 1970;4:18-21.
39. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
40. Bland JM. Statistics notes-trials randomised in clusters. BMJ 1997;315:600.
41. Blin O, Azorin JM, Lecrubier Y, Souche A, Fondarai J. The Psychotic Anxiety Scale (PAS). Evaluation of inter-rater reliability and correspondence factorial analysis. Encephale 1989 Nov-Dec;15(6):543-7.
42. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
43. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209-23.
44. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
45. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUTLASS 1). Archives of General Psychiatry 2006;63:1079-87.
46. Dahl SG. Pharmacokinetics of levomepromazine after single and multiple doses. Clinical Pharmacology and Therapeutics 1976;19(4):435-42.
47. Dahl SG, Bratlid T, Lingjaerde O. Plasma and erythrocyte levels of levomepromazine and two of its nonpolar metabolites in psychiatric patients. Therapeutic Drug Monitoring 1982;4:81-87.
48. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553-64.
49. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
50. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
51. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
52. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
53. Sproston K, Nazroo J. Ethnic minority psychiatric illness rates in the community (EMPIRIC) - Quantitative report. Department of Health -UK 2002.
54. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE. The European First Episode Schizophrenia Trial (EUFEST). The Lancet 2008;371(9618):1085-97.
55. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-76.
56. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the health survey for England. American Journal of Epidemiology 1994;149:876-83.
57. Guy W. Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): US National Institute of Health, Psychopharmacology Research Branch 1976:217-222.
58. Guy W. Abnormal involuntary movement scales. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): US National Institute of Health, Psychopharmacology Research Branch 1976:534-537.
59. Hals PA, Dahl SG. Metabolism of levomepromazine in man. European Journal of Drug Metabolism and Pharmacokinetics 1995;20(1):61-71.
60. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560.
61. Higgins JPT, Green S, editors. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1[updated September 2008]. The Cochrane Collaboration, 2008, 2008:187-35.
62. Gelder MG, Lopez-Ibor JJ, Nancy Andreasen N. Course and outcome of schizophrenia and their prediction. Oxford Textbook of Psychiatry. Vol. 1, Oxford University Press, 2000:612-21.
63. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323:42-46.
64. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch General Psychiatry 1988;45(9):789-96.
65. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS). Rating manual. San Rafael (CA): Social and Behavioural Science Documents 1987.
66. Lal S, Nair NP, Cecyre D, Quirion R. Levomepromazine receptor binding profile in human brain - implications for treatment-resistant schizophrenia. Acta Psychiatrica Scandinavica 1993;87(6):380-3.
67. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry 2001;50(11):884-97.
68. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
69. Moher D, Schulz KF, Altman D, The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;1987(285):91.
70. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
71. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care a systematic review. Health Technology Assessment 1999;3(5):1-75.
72. Xia J, Adams C. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Schizophrenia research 2008;3:137.